Browsing Category
Pharma Industry News
4733 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Breakthrough Parkinson’s research: Annovis says buntanetap improved cognition in patients with amyloid co-pathology
Discover why new biomarker data suggests amyloid co-pathology may accelerate cognitive decline in Parkinson’s and how buntanetap could help change treatment planning.
Atossa Therapeutics (NASDAQ: ATOS) expands (Z)-endoxifen to DMD: Will investors buy the thesis?
Atossa Therapeutics eyes new ground in DMD care with (Z)-endoxifen. Find out how this small molecule could reshape treatment for carriers and boys alike.
Why the FDA’s warning on Elevidys matters for Duchenne muscular dystrophy treatment
Sarepta’s Elevidys gene therapy now carries an FDA boxed warning. Find out what it means for Duchenne patients, investors, and gene therapy safety.
Why OSR Holdings (NASDAQ: OSRH) chose its scientific founder to lead Vaximm’s next immunotherapy chapter
OSR Holdings appoints scientific founder Dr. Andreas Niethammer as CEO of Vaximm AG to lead next-gen cancer immunotherapy strategy. Read more.
From boardroom to executive seat: Puccetti steps in as COSCIENS Biopharma interim chief
COSCIENS Biopharma taps Peter Puccetti as interim CEO to lead cost controls and commercial execution. Find out what this leadership change means for 2026.
Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC
Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care.
Sarepta Therapeutics (NASDAQ: SRPT) hit by FDA boxed warning as ELEVIDYS loses non‑ambulatory DMD indication
Sarepta’s ELEVIDYS gene therapy label now includes a boxed liver warning and removes non-ambulatory DMD use. Explore the safety updates and investor outlook.
Nuvalent (NASDAQ: NUVL) to release topline ALKOVE-1 trial data for neladalkib in advanced ALK-positive NSCLC on November 17
Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC on Nov 17. See what investors and analysts are expecting from ALKOVE-1.
Why Enveric Biosciences (NASDAQ: ENVB) may still be overlooked despite PTSD trial progress
Enveric stock dips despite FDA and PTSD progress on EB-003. Find out why investors are cautious and what milestones could restore confidence.
BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens
BrainStorm Cell Therapeutics narrows Q3 loss and prepares for pivotal ALS trial. Find out why 2026 could be a make-or-break year for the biotech company.